“Bisphosphonate 2.0”: Recent Advancements and Future Perspectives in Dentistry- A Narrative Review.

Author

Dr. B. LakshmanaRao , Dr. M. Pavan Kumar , Dr. D. Mahima Chowdary , Dr. D. Jagan Mohan Rao , Dr. B. Sanjay , Dr. K. Sai Pragna

Abstract

 Bisphosphonates are potent antiresorptive drugs primarily used to treat osteoporosis and to manage cancers. Because they bind well to bone and reduce osteoclast activity, they have become more important in dentistry. Recent studies now look beyond the risk of medication-related osteonecrosis of the jaw (MRONJ) and explore their use in treating gum disease, supporting dental implants, preserving jawbone, treating jaw conditions, and improving implant surfaces. Current evidence shows that using these drugs for osteoporosis does not, seem to raise the risk of dental implant failure, but long-term use may slightly increase the risk of MRONJ. Promising areas include delivering bisphosphonates directly to the mouth and using them on implant surfaces, though a 2026 review found insufficient evidence of clear clinical benefits. New research is focusing on targeted drug delivery, advanced implant coatings, managing the bone-immune environment, personalizing MRONJ risk, and more precise treatments. This review covers the latest developments and future possibilities for bisphosphonates in gum treatment, dental implants, oral surgery, and prosthodontics.

Keywords

Bisphosphonates; Antiresorptive drugs; Dentistry; MRONJ; Dental Implants; Implant surface modification; Bone remodeling.

Full Text:

Download Paper PDF

References

1.Liu H, Wang X, Shi Y, Yang Y, Li P, Chen Q, et al. Dual effects of bisphosphonates on bone metabolism and implant osseointegration: mechanisms, risks and clinical strategies. J Stomatol Oral Maxillofac Surg. 2025;126(6S):102534. doi:10.1016/j.jormas.2025.102534.

2.Pérez-González F, Sánchez-Labrador L, Sáez-Alcaide LM, López Carriches C, Méniz-García C. Does local bisphosphonate application or surface coating improve implant success? A systematic review. J Stomatol Oral Maxillofac Surg. 2026;127(4):102780. doi:10.1016/j.jormas.2026.102780.

3.Ali DS, Khan AA, Morrison A, Tetradis S, Mirza RD, El Rabbany M, et al. Antiresorptive therapy to reduce fracture risk and effects on dental implant outcomes in patients with osteoporosis: a systematic review and Osteonecrosis of the Jaw Taskforce consensus statement. Endocr Pract. 2025;31(5):686-698. doi:10.1016/j.eprac.2025.02.016.

4.Mirza RD, El Rabbany M, Ali DS, Tetradis S, Morrison A, Ruggiero S, et al. Dental implant failure and medication-related osteonecrosis of the jaw related to dental implants in patients taking antiresorptive therapy for osteoporosis: a systematic review and meta-analysis. Endocr Pract. 2025;31(9):1189-1196. doi:10.1016/j.eprac.2025.06.003.

5.Gangolu M, Jaswitha V, Boyapati R, Dhulipalla R, Maddukuri T, Pasupuleti SC. Bisphosphonates and periodontal health: a systematic review in postmenopausal women. J Midlife Health. 2025;16(4):371-385. doi:10.4103/jmh.jmh_120_25.

6.Al-Nawas B, et al. Group 3 ITI consensus report: materials and antiresorptive drug-associated outcomes in implant dentistry. Clin Oral Implants Res. 2023;34 Suppl 26:169-176.

7.Bisphosphonates – boon or bane for oral and maxillofacial surgery? Antiresorptive drugs and their potential role in dentistry and oral and maxillofacial surgery. J Cranio-Maxillofac Surg. 2025;53(12):2199-2209. doi:10.1016/j.jcms.2025.10.003.

Share your valuable work from Social Media Buttons